Abstract
No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55–86), median pretherapy PSA 206 ng/ml (range 42–10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1–6). Toxicity was mild, with only one patient manifesting serious (grade 3–4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a >75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. In summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC.
Similar content being viewed by others
References
Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997.Ca Cancer J Clin 47: 5–27, 1997
Roth BJ: Combination chemotherapy in advanced prostate carcinoma: a silk purse.J Clin Oncol 12: 2001–2002, 1994
Plowman J, Haugwitz RD, Narayanan VL, Baker DC, Hand ES, Rampal JB, Safavy A: Preclinical antitumor activity of pyrazine diazohydroxide, NSC 361456.Proc Amer Assoc Cancer Res 27: 275(#1089), 1986
Brodfuehrer JI, Moore DJ, Melder DC, Wilke TJ, Powis G: In vitrocytotoxicity of pyrazine-2–diazohydroxide: specificity for hypoxic cells and effects of microsomal co-incubation. Invest New Drugs 6: 3–9, 1988
Supko JG, Balcerak SP, Kraut EH: Phase I evaluation and pharmacokinetic study of pyrazine-2–diazohydroxide administered as a single bolus intravenous infusion in patients with advanced solid tumors.Can Res 53: 4843–4849, 1993
Vogelzang NJ, Mick R, Janisch L et al.: Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).Can Res 54: 114–119, 1994
Dhodapkar MV, Richardson RL, Reid JM and Ames MM: Pyrazine diazohydroxide (NSC-361456): Phase I clinical and pharmacokinetic studies.Invest New Drugs 12: 207–216, 1994
Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent.J Chronic Dis 13: 346–353, 1961
Harrison SD, Plowman J, Dykes DJ, Waud WR, Griswold DP Jr: Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.Can Chemo Pharmacol 25: 425–429, 1990
Kelly WK, Scher HI, Mazumdar M et al.: Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer.J Clin Oncol 11: 607–615, 1993
Sridhara R, Eisenberger MA, Sinibaldi VJ et al.: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy.J Clin Oncol 13: 2944–2953, 1995
Thalmann GN, Sikes RA, Chang S et al.: Suramin induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88: 794–801, 1996
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.J Clin Oncol 14: 1756–1764, 1996
Raghavan D: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs.Semin Oncol 15: 371–389, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edelman, M.J., Meyers, F.J., Grennan, T. et al. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. Invest New Drugs 16, 179–182 (1998). https://doi.org/10.1023/A:1006097109088
Issue Date:
DOI: https://doi.org/10.1023/A:1006097109088